Thu. 28 Jul 2022, 9:02am ET Benzinga News, FDA

Atossa Therapeutics, Inc. (NASDAQ:ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases with a current focus on breast cancer and COVID-19, today announces it has completed dosing participants in Part C of its Phase 1/2a clinical study of its proprietary inhalation therapy (or, AT-H201) in Australia.